Clinical Trials Directory

Trials / Completed

CompletedNCT04801446

Transcranial Direct Current Stimulation in Acute Ischemic Stroke Treatment

Transcranial Direct Current Stimulation in Acute Ischemic Stroke Treatment - Safety and Feasibility Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
25 (actual)
Sponsor
General University Hospital, Prague · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This prospective interventional single center randomized sham controlled dose-escalation study will assess safety, tolerability, feasibility and potential efficacy of transcranial direct current stimulation (tDCS) in acute stroke patients with substantial salvageable penumbra due to a large vessel occlusion who are ineligible for endovascular therapy (EVT). Patients will be randomized in a 3:1 design, to cathodal versus sham (control) tDCS, at each six designed dose tiers. The dose tiers will be increasing in both intensity and duration of the stimulation. The occurrence of symptomatic intracranial hemorrhage will determine the pace of the escalation through the dose tiers.

Conditions

Interventions

TypeNameDescription
DEVICESoterix Medical 1X1 tDCS stimulator (active C-tDCS)Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
DEVICESoterix Medical 1X1 tDCS stimulator (sham stimulation)Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.

Timeline

Start date
2021-05-10
Primary completion
2023-11-13
Completion
2024-02-10
First posted
2021-03-17
Last updated
2024-08-06

Locations

1 site across 1 country: Czechia

Source: ClinicalTrials.gov record NCT04801446. Inclusion in this directory is not an endorsement.